| Object: Stanniocalcin (stanniocalcin 1, STC1) is a class of glycoprotein hormones, which was first founded in bony fish and in recent years has been found in human and mammalian. STC1 paracrine manner is involved in a variety of physiological functions of the body, not only through the kidneys and the intestinal system to regulate calcium and phosphate in the steady state, but also in promoting neurons in the terminal differentiation, and prevent ischemic brain damage caused by neurons, as well as bone and muscle development and so have an important role. Recent studies have found, STC-1 also plays an important role in human tumor development and the process. Research has shown that STC-1 can be used as a stabilizing factor in the promotion of new blood vessels mature to play a role in promoting the growth of tumor proliferation; STC-1 can also pass through autocrine tumor cell surface chemokine and integrin interactions, activation of a series of intracellular signaling, causing a variety of protein synthesis, secretion, thereby dissolving the extracellular matrix barrier to tumor invasion and transfer. This paper discusses the target genes of human stanniocalcin 1 (human stanniocalcin-1, hSTC1) expression in colorectal cancer in different periods. To investigate the correlation between the types and clinical, pathological stage and metastasis; to understand STC1 in different pathological stages expression in cancer patients, and to explore whether the two is related to each other. Meanwhile, it is also to explore whether STC1 can be a new tumor marker for clinical patients, thereby to enhance the rate of digestive system tumors, and to provide the experimental basis for the tumors of early diagnosis, early treatment and prognosis. Experimental Methods: This study applies enzyme-linked immunosorbent assay (the ELISA), measuring 20 healthy volunteers and 40 patients with colon cancer before 2 weeks after surgery with serum STC-1 expression, by using immunohistochemistry staining method to detect the STC-1 protein expression in 40 cases of colon cancer and 20 normal colon tissue. Process and analyze STC-1 tumor gene expression and clinical pathological data by using SPSS11.5 statistical software.Results: The positive rate of STC-1 in 40 cases of colon cancer tissue was 72.50% (29/40), including 22 cases with metastasis, whose positive rate was 81.82% (18/22); STC-1 positive rate in 40 cases of colon cancer patients well-differentiated group and in the poorly differentiated group was 57.1% (8/14) and58.82% (10/17) . STC-1 expression in Metastasis group and no metastasis group was81.82% and 55.56% .20 cases of normal tissues are with no expression of STC-1. The statistical analysis in colon cancer patients, the average STC-1 expression in the normal population and patients with colon cancer, colon cancer patients and the early transfer of patients as well as between high and low degree of differentiation in colon cancer and metastasis were with statistical significance.Conclusion:1. There is almost no SCT-1 expression in the normal adult serum. SCT-1 expression was significantly higher in patients with colon cancer, and its expression is related to the tumor differentiation and prognosis, that is, the expression is higher if the differentiation degree is lower and/or prognosis is worse.2. There is almost no SCT-1 expression in the normal adult serum. SCT-1 expression was significantly higher in patients with colon cancer.3. Levels of STC-1 expression in colon cancer risk of tissue and serum are associated with tumor metastasis; its expression levels were higher in those with metastasis than those without metastasis. 4. STC-1 may serve as a new colon tumor mark for tumor differentiation and prognosis of prompting. |
PDF Full Text Request